Christine Katlama and Babafemi Taiwo: Answering the Questions on Optimizing Antiretroviral Therapy in Heavily Treatment–Experienced People With HIV

In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:

• Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimens
• Maintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABC
• ART regimen simplification
• When to perform genotypic resistance testing, including for PWH who have been off ART
• When to perform DNA genotyping for archived resistance testing
• Considering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ART
• Using boosted DRV + DTG in salvage regimens
• Switching from boosted PIs to INSTIs in PWH receiving second-line therapy
• Second-line regimens with LA CAB + RPV failure 

Christine Katlama, MD 
Professor 
Sorbonne University APHP Paris 
Head, HIV/Hepatitis Clinical and Research Unit 
Department of Infectious Diseases 
Paris, France 

Babafemi Taiwo, MBBS 
Gene Stollerman Professor of Medicine 
Chief, Division of Infectious Diseases 
Northwestern University Feinberg School of Medicine 
Chicago, Illinois 

Link to full program: https://bit.ly/3Z44Gq3

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.